CLAIMS

1. A pharmaceutical composition comprising a fibroblast highly expressing ADM and/or HHEX.

2. The pharmaceutical composition according to claim 1, wherein the fibroblast is an adult-derived fibroblast.

3. The pharmaceutical composition according to claim 1 or 2, wherein gene expression level(s) of ADM and/or HHEX in the fibroblast are/is 1.20 times or higher as compared with a control fibroblast.

4. Use of the pharmaceutical composition according to any one of claims 1 to 3 in the manufacture of a medicament for treating fibrosis.

5. Use of the pharmaceutical composition according to any one of claims 1 to 3 in the manufacture of a medicament for amelioration of a condition of reduced lymphangiogenesis ability.

6. Use of the pharmaceutical composition according to any one of claims 1 to 3 in the manufacture of a medicament for amelioration of a disorder of homeostasis in a tissue fluid.

7. Use of the pharmaceutical composition according to any one of claims 1 to 3 in the manufacture of a medicament for reduction of edema.

8. Use of the pharmaceutical composition according to any one of claims 1 to 3

in the manufacture of a medicament for amelioration of a disorder of transportability of lipid and/or vitamin.

9. Use of the pharmaceutical composition according to any one of claims 1 to 3 in the manufacture of a medicament for activation of an immunological surveillance mechanism.

10. The pharmaceutical composition according to any one of claims 1 to 9, wherein the pharmaceutical composition is an injectable composition.

11. The pharmaceutical composition according to any one of claims 1 to 9, wherein the fibroblast is constructed as a planar or three-dimensional cellular tissue.

12. The pharmaceutical composition according to any one of claims 1 to 11, wherein the fibroblast is a cardiac fibroblast.

13. A method for producing a fibroblast highly expressing ADM, comprising:

contacting TNF-α and IL-4 with a fibroblast; and

culturing the fibroblast contacted, under a condition where ADM is capable of being highly expressed.

14. The method according to claim 13, wherein the fibroblast highly expresses VEGF-C.

15. The method according to claim 13 or 14, wherein the fibroblast is CD106-positive.

16. The method according to claim 15, comprising selecting or concentrating a fibroblast highly expressing ADM, by use of an anti-CD106 antibody.

17. The method according to any one of claims 13 to 16, wherein the fibroblast is a pulmonary fibroblast.

18. A fibroblast highly expressing ADM, obtained by the method according to any one of claims 13 to 17.

19. A cell population of fibroblasts comprising the fibroblast according to claim 18.

20. A fibroblast highly expressing ADM.

21. The fibroblast according to claim 20, wherein the fibroblast highly expresses VEGF-C.

22. The fibroblast according to claim 20 or 21, wherein the fibroblast is CD106-positive.

23. The fibroblast according to any one of claims 20 to 22, wherein gene expression level(s) of VEGF-C and/or ADM in the fibroblast are/is 1.20 times or higher as compared with a control fibroblast.

24. The fibroblast according to any one of claims 20 to 23, wherein the fibroblast is a pulmonary fibroblast.

25. A cell population of fibroblasts comprising the fibroblast according to any one of claims 20 to 24.

26. A cell population comprising a CD106-positive pulmonary fibroblast, wherein the proportion (based on the number of cells) of the CD106-positive pulmonary fibroblast in the total fibroblast contained in the cell population is more than 18.01%.

27. A pharmaceutical composition comprising the fibroblast according to any one of claims 18 and 20 to 24 or the cell population according to any one of claims 19 and 25 to 26.

28. Use of the pharmaceutical composition according to claim 27 in the manufacture of a medicament for treating a pulmonary disease.

29. The use according to claim 28, wherein the pulmonary disease is pulmonary fibrosis or interstitial pneumonia.

30. Use of the pharmaceutical composition according to claim 27 in the manufacture of a medicament for amelioration of a condition of reduced lymphangiogenesis ability.

31. The pharmaceutical composition according to any one of claims 27 to 30, wherein the pharmaceutical composition is an injectable composition.

32. The pharmaceutical composition according to any one of claims 27 to 30, wherein the fibroblast or the cell population is constructed as a planar or three-

dimensional cellular tissue.